Class A Common Stock, $0.0001 par value per share
- Symbol
- CELU
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Celularity Inc.
CELUNASDAQEQUITYCurrent
Other Events
Item 8.01. Other Events. On October 29, 2026, Celularity Inc. (“Celularity”) issued a press release announcing an exclusive manufacturing and commercial collaboration with Vesalius Longevity Labs Inc. (“Vesalius”), for U.S.-based purification, processing, analytical testing and manufacture of peptide active pharmaceutical ingredients under Vesalius’s Peptual® brand.…
Company context
Current securities
Registered securities in this filing
Celularity Inc. · 8-K · Filed 2026-10-29
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item
8.01. Other Events.
On
October 29, 2026, Celularity Inc. (“Celularity”) issued a press release announcing an exclusive manufacturing and commercial
collaboration with Vesalius Longevity Labs Inc. (“Vesalius”), for U.S.-based purification, processing, analytical testing
and manufacture of peptide active pharmaceutical ingredients under Vesalius’s Peptual® brand.
The
collaboration pairs Celularity’s manufacturing infrastructure and technical expertise with Vesalius’s Peptual platform to
advance U.S.-based production of peptide APIs in accordance with current good manufacturing practice standards at Celularity’s
New Jersey facility. The parties intend to establish a domestic supply platform that supports consistent product quality and lot-level
traceability while strengthening the resilience and accountability of the peptide API supply chain.
A
copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Filed exhibits (1)
Exhibit 99.1 Celularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States Celularity to serve as the exclusive partner for the finish manufacturing of Vesalius’s Peptual peptide APIs, supporting Vesalius’s expansion into pharmaceutical ingredient supply Collaboration advances Celularity’s regenerative longevity vision and creates an opportunity to expand revenue through its U.S. manufacturing infrastructure and technical expertise FLORHAM PARK, N.J. and SCOTTSDALE, A.Z., October 29, 2026 - Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, and Vesalius Longevity Labs Inc. (“Vesalius”), a leading, global peptide and longevity brand, today announced that they have entered into an exclusive manufacturing agreement to establish a dedicated, first-of-its-kind, U.S. final stage API manufacturing and supply platform for Vesalius’s Peptual-branded active pharmaceutical ingredients (“APIs”). The collaboration expands Celularity’s regenerative longevity platform by applying Celularity’s U.S.-based manufacturing infrastructure and technical capabilities to suppor…
Open exhibit ↗